Pathogenic variants of DNAJC12 and evaluation of the encoded cochaperone as a genetic modifier of hyperphenylalaninemia by Gallego, Diana et al.
Repositorio Institucional de la Universidad Autónoma de Madrid 
https://repositorio.uam.es  
Esta es la versión de autor del artículo publicado en: 
This is an author produced version of a paper published in:
Human Mutation (2020): 25 April
DOI: https://doi.org/10.1002/humu.24026
Copyright: © 2020 Wiley Periodicals Inc. 
                     
El acceso a la versión del editor puede requerir la suscripción del recurso 
Access to the published version may require subscription 
 
This article has been accepted for publication and undergone full peer review but 
has not been through the copyediting, typesetting, pagination and proofreading 
process, which may lead to differences between this version and the Version of 
Record. Please cite this article as doi: 10.1002/humu.24026. 
 
This article is protected by copyright. All rights reserved. 
 
Aurora Martinez    ORCID iD: 0000-0003-1643-6506 
Belen Pérez    ORCID iD: 0000-0002-3190-1958 
Pathogenic variants of DNAJC12 and evaluation of the 
encoded co-chaperone as a genetic modifier of 
hyperphenylalaninemia 
Gallego, Diana1; Leal, Fátima1; Gámez, Alejandra1, Castro, Margarita1; Navarrete, 
Rosa1; Sanchez-Lijarcio, Obdulia1; Vitoria, Isidro2; Bueno-Delgado, María3; 
Belanger-Quintana, Amaya4; Morais, Ana5; Pedrón-Giner, Consuelo6; García, 
Inmaculada7; Campistol, Jaume8; Artuch, Rafael8; Alcaide, Carlos9; Cornejo, 
Veronica10; Gil, David11; Yahyaoui, Raquel12; Desviat, Lourdes R.1; Ugarte, 
Magdalena1; Martínez, Aurora13; Pérez, Belén1 
1 Centro de Diagnóstico de Enfermedades Metabólicas, Centro de Biología 
Molecular, Universidad Autónoma de Madrid, Madrid. CIBERER, IdiPAZ, Spain 
2 Hospital Universitario La Fe, Valencia, Spain 
3 Hospital Virgen del Rocío, Seville, Spain 
4 Hospital Universitario Ramón y Cajal, Madrid, Spain 
5 Hospital Universitario La Paz, Madrid, Spain 
6 Hospital Infantil Universitario Niño Jesús, Madrid, Spain 
7 Hospital Universitario Miguel Servet, Zaragoza, Spain 
 
This article is protected by copyright. All rights reserved. 
 
8 Institut de Recerca and Hospital Universitario Sant Joan de Déu, Barcelona; 
CIBERER, Spain 
9 Hospital Universitario Río Hortega, Valladolid, Spain 
10 INTA, Santiago de Chile, Chile  
11 Hospital Virgen de la Arrixaca, Murcia, Spain 
12 Hospital Regional Universitario de Málaga; Instituto de Investigación Biomédica 
de Málaga-IBIMA, Spain 
13 Department of Biomedicine, University of Bergen, 5009 Bergen, Norway 
Corresponding author:  
Belén Pérez bperez@cbm.csic.es 
Authors have not any conflict of interest  
Grant numbers: PI16/00573; B2017/BMD-3721; (LCF/PR/PR16/11110018) 
ABSTRACT 
Biallelic variants of the gene DNAJC12, which encodes a co-chaperone, were 
recently described in patients with hyperphenylalaninemia (HPA). This paper 
reports the retrospective genetic analysis of a cohort of unsolved cases of HPA. 
Biallelic variants of DNAJC12 were identified in 20 patients (generally 
neurologically asymptomatic) previously diagnosed with phenylalanine 
hydroxylase (PAH) deficiency (phenylketonuria, PKU). Further, mutations of 
DNAJC12 were identified in four carriers of a pathogenic variant of PAH. The 
genetic spectrum of DNAJC12 in the present patients included four new variants, 
 
This article is protected by copyright. All rights reserved. 
 
two intronic changes c.298-2A>C and c.502+1G>C, presumably affecting the 
splicing process, and two exonic changes c.309G>T (p.Trp103Cys) and c.524G>A 
(p.Trp175Ter), classified as variants of unknown clinical significance (VUS). The 
variant p.Trp175Ter was detected in 83% of the mutant alleles, with 14 cases 
homozygous, and was present in 0.3% of a Spanish control population. Functional 
analysis indicated a significant reduction in PAH and its activity, reduced TH 
stability, but no effect on TPH2 stability, classifying the two VUS as pathogenic 
variants. Additionally, the effect of the overexpression of DNAJC12 on some 
destabilising PAH mutations was examined and a mutation-specific effect on 
stabilization was detected suggesting that the proteostasis network could be a 
genetic modifier of PAH deficiency and a potential target for developing mutation-
specific treatments for phenylketonuria.  
Keywords: DNAJC12, hyperphenylalaninemia, phenylketonuria, molecular 
chaperones, proteostasis network 
INTRODUCTION 
Hyperphenylalaninemia (HPA) is an inherited metabolic condition defined 
by increased blood phenylalanine (Phe) concentrations (>120 µmol/L). In 98% of 
cases, it results from a loss-of-function mutation in the PAH gene, which codes for 
the hepatic enzyme phenylalanine hydroxylase (PAH, EC1.14.16.1) responsible for 
the conversion of Phe to tyrosine (Tyr) in the presence of the cofactor 
tetrahydrobiopterin (BH4). PAH deficiency or phenylketonuria (PKU; MIM# 
261600), one of the most common of all inborn errors of metabolism, affects 
approximately 1 in 10,000 newborns. Untreated (notably for blood Phe levels >600 
µmol/L) it leads to progressive and irreversible intellectual disability, along with 
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motor deficits and other neurological problems (Blau, van Spronsen, & Levy, 
2010). The remaining 2% of cases of HPA are caused by defects in either the 
synthesis or regeneration of BH4 and involve a more complex neurological 
phenotype; BH4 acts also as a cofactor for tyrosine hydroxylase (TH, EC: 
1.14.16.2) as well as for tryptophan hydroxylase 1 and 2 (TPH, EC: 1.14.16.4), the 
rate-limiting enzymes in the synthesis of the neurotransmitters dopamine and 
serotonin respectively. Low concentrations of dopamine and the serotonin 
metabolites homovanillic acid (HVA) and 5–hydroxyindoleacetic acid (5–HIAA) 
in cerebrospinal fluid (CSF) may indicate a neurotransmitter deficit (Brennenstuhl, 
Jung-Klawitter, Assmann, & Opladen, 2019). 
PKU treatment is focused on maintaining blood Phe below toxic levels and 
relies on life–long dietary restriction - although one subset of patients has shown a 
favourable genotype–dependent response to oral sapropterin (the commercial form 
of BH4) supplementation (Erlandsen et al., 2004). For deficiencies in BH4 
metabolism, additional treatment with neurotransmitter precursors such as L–
DOPA (for dopamine) plus carbidopa and 5–hydroxytryptophan (for serotonin) 
may be required (Blau, 2016).  
The early diagnosis of HPA and the immediate start of treatment 
appropriate for the specific gene defect detected can prevent neurological 
symptoms and allow normal development. In many developed countries, HPA 
detection has been included in neonatal screening programmes for over 50 years. A 
positive result for HPA is followed by a differential biochemical diagnosis to 
identify a possible defect in BH4 synthesis or regeneration. Genetic confirmation is 
mandatory before prescribing a tailored therapy (Vockley et al., 2014). 
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In several patients with neither genetic defect in PAH, nor in any gene 
involved in BH4 metabolism, biallelic mutations in DNAJC12 have been reported 
to cause HPA accompanied by heterogeneous neurological symptomatology or 
early–onset Parkinsonism (Anikster et al., 2017), (van Spronsen et al., 2017), 
(Straniero et al., 2017). DNAJC12 belongs to the DNAJ/Hsp40 family of co-
chaperones that modulate the activity of molecular chaperone Hsp70 and mediate 
the productive delivery of its substrates (Choi, Djebbar, Fournier, & Labrie, 2014). 
Hsp70 is involved in a wide range of cellular processes, including the de novo 
folding of nascent chains and the refolding of aggregation-prone folding 
intermediates or misfolded proteins (Kampinga & Craig, 2010). DNAJC12 directly 
interacts with PAH, TH and TPH in human cells, and is therefore thought to play a 
critical role in the Hsp70–assisted folding of aromatic amino acid hydroxylases 
(AAAH) (Anikster et al., 2017). Moreover, a recent investigation has shown that 
DNAJC12 may play a role in the processing of misfolded ubiquitinated PAH, 
adding to the evidence that DNAJ proteins are important for the proper folding and 
degradation of their clients (Jung-Kc et al., 2019). 
The complete structure of DNAJC12 is still to be determined, and little is 
known about the mechanism by which this co-chaperone exerts its function. Along 
with the rest of the Hsp40 family, DNAJC12 shares the conserved N-terminal JDP 
domain with the motif HPD that interacts with the molecular chaperone Hsp70, 
promoting its ATPase activity (Qiu, Shao, Miao, & Wang, 2006). The other major 
distinguishing feature of DNAJC12 is its highly conserved C–terminal 
heptapeptide KFRNYEI, which has been suggested involved in specific client 
binding (Hahn, Lee, Seong, Yoon, & Chung, 1999), (Lee, Hahn, Yun, Mita, & 
Chung, 2000).  
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The proteostasis network coordinates the balance between protein synthesis, 
folding and degradation. Molecular chaperones such as Hsp70 and their partners, 
constitute a complex machinery that guides the folding of nascent peptides and the 
refolding of stress–unfolded proteins, and/or facilitates their degradation when no 
recovery is possible (Kampinga & Craig, 2010). To avoid the accumulation of 
potentially toxic aggregates, the cell attempts to degrade meta-stable or aberrant 
polypeptides due to hypomorphic mutations (Dekker, Kampinga, & Bergink, 
2015). Hsp70 recognizes the substrates fated for break-down and delivers them to 
downstream partners in the degradation pathway (Mayer & Gierasch, 2019). 
DNAJC12 might drive the specificity of this process.  
PKU is a conformational disease, and about 80% of PAH mutations are 
missense variants that cause PAH destabilization and accelerated degradation, 
leading to the loss–of–function phenotype and the manifestation of disease 
(Gersting et al., 2008), (Scheller et al., 2019). However, some inconsistencies in 
genotype–phenotype correlation and BH4 responsiveness have been observed in 
certain patients with destabilizing mutations (Aldamiz-Echevarria et al., 2016), 
(Gamez, Perez, Ugarte, & Desviat, 2000). This lack of correlation may be 
explained by other genes acting as modifiers of disease severity (Citro et al., 2018). 
Genes involved in protein folding and stability, such as those coding for molecular 
chaperones and other proteostasis network components, may influence the 
association between genotype and phenotype in conformational disorders (Scriver, 
2007). 
Our laboratory is a reference centre for the genetic study of HPA in Spain. 
Of the 1407 HPA cases dealt with, biochemical differential diagnosis classified 
98.5% under PAH deficiency. Biallelic mutations in PAH were found in 95% of 
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cases. The remainder cases had only a monoallelic variant or had no PAH mutation. 
The purpose of the present work was to identify possible defects in DNAJC12 that 
might be the genetic cause of HPA in these latter cases, thus helping in the 
structuring of a tailored therapy and in the provision of appropriate genetic 
counselling. In addition, the potential of DNAJC12 overexpression as a means of 
ameliorating the destabilizing effects of PAH mutations was examined. 
MATERIALS AND METHODS 
Patient clinical features  
This retrospective study examines a cohort of patients with HPA (n=50), all with a 
biochemical suspicion of PAH deficiency but without biallelic mutations in PAH. 
All had Phe levels of >120 µM (120–442 µM) at diagnosis, and had normal DHPR 
activity and urinary pterin levels. Sanger analysis was used to sequence the exonic 
region of DNAJC12. Nomenclature of the variants was verified using 
VariantValidator (https://variantvalidator.org/). All of the variations reported in 
this work were described with reference to DNAJC12 transcript NM_021800.3 or 
PAH transcript NM_000277.3. Variants in DNAJC12 were submitted to the LOVD 
(http://www.lovd.nl/) and ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) 
databases. All these variants were classified according to ACMG guidelines, by the 
Varsome platform (Kopanos et al., 2019). The study protocol adhered to the 
Declaration of Helsinki and was approved by the Ethic Committee of Universidad 
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Functional studies 
Patient-derived fibroblasts carrying biallelic mutations in DNAJC12 (taken 
with informed consent) were grown following standard conditions in minimal 
essential medium (MEM) supplemented with 1% glutamine, 10% fetal bovine 
serum (FBS) and antibiotics (penicillin and streptomycin). 
For expression analyses, control and patient–derived fibroblasts were plated 
(2 x 106 cells) in 100 mm culture dishes, and on the following day transfected with 
5 µg of the plasmids pRC-CMV-PAH, pCDNA3-TH (the kind gift of Dr. Angels 
García–Cazorla, Barcelona, Spain) or pCMV6-TPH2 (SinoBiological) using 25 µl 
of Lipofectamine 2000 reagent (ThermoFisher Scientific) according to the 
manufacturer’s instructions.  
For overexpression studies, COS–7 cells were plated in six–well plates at 3 
x 105 cells per well and transfected with 1 µg of pRC-CMV-PAH expressing either 
wild–type PAH or one of several PAH mutants (p.Leu48Ser, p.Ile65Thr, 
p.Arg261Gln, p.Glu280Lys, p.Leu348Val or Val388Met). Alternatively, they were 
co–transfected with the pReceiver/DNAJC12 plasmid (OriGene) using the jetPEI 
transfection reagent (Polyplus). In all cases, transfected cells were harvested with 
trypsin after 48 h.  
For the functional analysis of DNAJC12 variants, 250 ng of total RNA 
isolated from control and patient–derived fibroblasts were retrotranscribed using 
the NZY First Strand cDNA Synthesis Kit (NZYTech). DNAJC12 was amplified 
from the obtained cDNA with the specific primers 
CAGTGAAGACGTCAATGCACT and GGTTGAAGCCAGCTCCTCT, and 
using the Perfecta SYBR Green Fast Mix Kit (Quanta Biosciences). GAPDH was 
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used as an endogenous control. qPCR reactions were performed in triplicate in a 
Light Cycler 480 II instrument (Roche Applied Bioscience). After determining the 
raw threshold cycle (Ct) values for the reference and target genes, the relative 
quantification (RQ) or fold–change was calculated according to the 2-ΔΔCt method.  
For protein analysis, total protein was extracted from fibroblasts or COS–7 
cells using cOmpleteTM Lysis-M buffer (Sigma-Aldrich) and protease inhibitor 
(Sigma-Aldrich) and its concentration determined via the Bradford assay (BioRad). 
Equal amounts of protein extract were prepared in NuPage®LDS 4x sample buffer 
(Invitrogen) and dithiothreitol (DTT) and subjected to electrophoresis in 4-12% 
NuPAGE Novex Bis–Tris precast polyacrylamide gel (Invitrogen). Proteins were 
transferred to a nitrocellulose membrane using the iBlot 2 Dry blotting system 
(Invitrogen). Membranes were blocked after 1 h with Tris-buffered saline (TBS) 
containing 5% non–fat dry milk and 0.1% Tween–20. Immunodetection was 
performed using commercially available antibodies against DNAJC12 (1:750, 
Abcam), PAH (1:1000, Santa Cruz Biotechnology), TH (1:1000, Sigma–Aldrich) 
and TPH2 (1:1000, Sigma–Aldrich). NPT-II (1:1000, Millipore) was used as a 
marker of plasmid transfection efficiency and β-actin (1:5000, Abcam) as a loading 
control to normalize the amount of protein. After incubation with secondary 
antibody (anti–rabbit 1:5000 or anti–mouse 1:2000 [Cell Signalling]), protein 
bands were detected using SuperSignal™ West Femto Maximum Sensitivity 
Substrate (ThermoFisher Scientific).  
PAH activity assays 
The freeze–thaw method was used to lyse PAH–transfected fibroblasts and COS–7 
cells. PAH activity was assayed at 25°C in a final volume of 50 µl. 10 µg of total 
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protein extract were mixed with Na–Hepes Buffer pH 7.0, 0.1 mg/ml catalase and 1 
mM L–Phe and incubated for 5 min, adding 1 µM Fe(NH4)2(SO4)2 for the last 
minute. The reaction was started by the addition of 75 µM (6R)–
tetrahydrobiopterin (BH4) and 5 mM DTT and incubated for 30 min; it was 




Of the 50 patients studied, 21 had variants in DNAJC12. Tables 1 and 2 
summarize the patients' genotypes and phenotypes. The Phe levels at diagnosis 
ranged from 120 to 442 µM. All patients had normal DHPR activity and normal 
urinary pterin levels. CSF analysis for pterins and neurotransmitter metabolites 
HVA and 5-HIAA was performed for two patients (P13 and P17). P17 had normal 
levels for all of these, but P13 showed a slight reduction in HVA and 5-HIAA. Of 
the above 21 patients, 19 followed a normal diet. The Phe intake of P14 was 
limited during pregnancy, and P6 remains subject to mild Phe restriction. Only two 
patients (P7 and P13) have received treatment with sapropterin; P7 was treated 
with doses of 5-6 mg/kg (from 14 months to six years of age) and P13 with 10 
mg/kg (from the 3 to 8 years of age). Some other patients showed an increase in 
Phe (400–500 µM) during febrile processes and were treated with sapropterin. 
Only four patients of the above 21 showed constant clinical symptoms, including 
psychomotor delay and seizures, autism symptoms or hyperactivity. No patient had 
Parkinsonism. Schooling was normal in all cases; only P10 and P16 needed some 
learning support. Among those with neurological symptoms, only P6 was 
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administered neurotransmitter precursors. The remaining patients are currently 
untreated. 
Sanger sequencing revealed 20 patients with biallelic variants in DNAJC12, 
leading to the identification of four unreported nucleotide changes: c.298-2A>C, 
c.309G>T (p.Trp103Cys), c.502+1G>C and c.524G>A (p.Trp175Ter). Three 
patients homozygous for the p.Trp175Ter variant and one heterozygous also 
presented the following monoallelic variants in PAH: c.194T>C (p.Ile65Thr), 
c.143T>C (p.Leu48Ser), c.912+1G>A (p.?) and c.441+5G>T (p.?) (P18–P21).  
The changes c.298-2A>C, c.502+1G>C and p.Trp103Cys in DNAJC12 
were not detected in the gnomAD worldwide population database, nor in the 
Spanish database. The splicing variants were predicted to be pathogenic according 
to the rules of the American College of Medical Genetics (ACMG) (Richards et al., 
2008), by the Varsome platform (Kopanos et al., 2019), while the variants 
p.Trp103Cys and p.Trp175Ter were classified as VUS. The nonsense variant 
p.Trp175Ter, which causes the introduction of a premature termination codon in 
the last exon of DNAJC12, was detected in 80% of the variant alleles. This change 
is recorded in the gnomAD database and in a Spanish consortium database with 
frequencies of under 0.016% and 0.3%, respectively. It would appear to be 
particularly common in the Latino population, although no homozygous control 
individuals were found in the population databases consulted.  
Given that in silico analysis failed to determine the pathogenicity of the 
p.Trp175Ter and p.Trp103Cys variants, functional assays were needed to offer a 
reliable diagnosis with clinical significance.  
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Functional effect of DNAJC12 variants  
Primary skin fibroblasts derived from three cases with DNAJC12 
deficiency (P14, P16 and P20) were used to assess the functional effect of the 
p.Trp175Ter and p.Trp103Cys variants on DNAJC12 expression at the 
transcriptional and protein levels. Both P14 and P20 were homozygous for the 
p.Trp175Ter variant, and P16 presented p.Trp175Ter in compound heterozygosity 
with the p.Trp103Cys variant. P20 also carried a mutated PAH allele. Quantitative 
real time PCR (qPCR) analysis showed a reduction in DNAJC12 mRNA levels in 
all three patients' fibroblasts compared to three healthy, unrelated controls (Fig. 
1A). Immunoreactive DNAJC12 p.Trp175Ter protein was undetectable by Western 
blot in the patients' fibroblasts. The introduction of a premature termination codon 
in the last exon of DNAJC12 led to a protein lacking the last 23 amino acids from 
the C–terminus, preventing its recognition by commercially available antibodies. In 
the case of the compound heterozygous P16 (p.Trp103Cys/p.Trp175Ter), protein 
levels were slightly diminished (Fig. 1B).  
DNAJC12 has been proposed to play a key role in the proper folding of 
PAH, TH and TPH (Anikster et al., 2017). To gain further insight into the 
pathomechanisms related to the DNAJC12 deficiency of the present patients, the 
steady–state levels of the three aromatic amino acid hydroxylases (AAAH) in the 
presence of the p.Trp175Ter and p.Trp103Cys variants were determined. Given 
that these hydroxylases are not expressed in primary skin fibroblasts, control and 
patient–derived fibroblast lines were transfected with plasmids coding for PAH, 
TH and the neurological isoform of the TPH protein (TPH2). Western blot analysis 
revealed a pronounced reduction in PAH and TH protein levels in the presence of 
the DNAJC12 variants (Fig. 2A and C). Correlating with these results, PAH 
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enzymatic activity was markedly reduced (Fig. 2B). Nevertheless, no difference in 
the TPH2 expression profile was seen between the control and patients’ cells under 
the present study conditions (Fig. 2D), suggesting that the p.Trp175Ter and 
p.Trp103Cys variants may have a greater effect on PAH and TH stability than that 
of TPH. Moreover, DNAJC12 levels were intriguingly reduced after the 
transfection of hydroxylase cDNA, probably pointing to some intracellular co-
aggregation. Taken together, these data support the pathogenic nature of these 
DNAJC12 variants, explaining the HPA observed in the present cases.  
Role of DNAJC12 in the presence of PAH mutants 
As described above, protein misfolding is the main pathomechanism in 
PKU, with most of the missense mutations affecting PAH folding and stability 
(Gersting et al., 2008). Boosting DNAJC12 expression might offer a therapeutic 
option for PKU. To this end, wild–type DNAJC12 was overexpressed in COS–7 
cells transfected with wild–type or different PAH mutants previously characterized 
by our group: p.Leu48Ser, p.Ile65Thr, p.Arg261Gln, p.Glu280Lys, p.Leu348Val 
and Val388Met (Gamez et al., 2000). These mutations have been associated with 
discrepancies between in vitro residual activity and patient clinical phenotype, as 
well as with some inconsistencies in the response to sapropterin (Aldamiz-
Echevarria et al., 2016). The resulting effect on PAH was examined via Western 
blotting and enzyme activity assays. Unexpectedly, DNAJC12 overexpression 
triggered an increase in protein levels for the p.Leu48Ser, p.Ile65Thr and 
p.Arg261Gln PAH mutants, correlating with enhancements of enzyme activity of 
23, 5.2, 1.4 and 2.8-fold respectively. In the case of the remaining mutants, PAH 
levels were reduced after DNAJC12 co–transfection (Fig. 3). This mutation-
dependent result might reflect a selective DNAJC12 function in the presence of 
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different PAH mutants, guiding the Hsp70 machinery towards the specific folding 
or degradation of the client protein.  
DISCUSSION 
The present work reports the detection of 20 patients with HPA carrying 
new biallelic variants of DNAJC12, and one with a pathogenic variant in that gene. 
Four patients also bore a pathogenic variant in PAH. These last four patients had 
been previously classified as having PAH deficiency and had been treated in 
accordance with that misdiagnosis. All had plasma Phe levels corresponding to a 
benign HPA phenotype, and all presented biochemical hallmarks similar to those of 
PAH deficiency (Blau, Martinez, Hoffmann, & Thony, 2018). This shows it is 
important to conduct retrospective genetic analysis for all unsolved cases of HPA, 
regardless of the presence of neurological symptoms, since in our cohort only four 
subjects had clinical symptoms. The remaining unsolved 29 of the 50 cases might 
bear pathogenic variants in regulatory or intronic sequences of PAH or DNAJC12, 
or in other genes which phenocopy PAH or DNAJC12 deficiencies. Genomic or 
transcriptional analysis should be performed so that tailored therapy can be 
prescribed. 
Two loss–of–function variants were identified - c.298-2A>C and 
c.502+1G>C - affecting the 3’ and 5’ conserved splice sites of exon 4 respectively 
(they were hence considered pathogenic variants). In addition, two exonic 
nucleotide changes were identified - p.Trp103Cys and p.Trp175Ter - classified as 
VUS according to ACMG rules (Richards et al., 2008). Taking into account this 
classification, and the high frequency of p.Thr175Ter in the general Spanish 
population, functional genomic analysis was deemed necessary. The results 
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revealed both VUS variants to be pathogenic. After transfection with PAH cDNA, 
the reduction in the amount of PAH and PAH activity observed in fibroblasts 
derived from two patients homozygous for the p.Trp175Ter variant, and in those of 
one patient compound heterozygous for p.Trp103Cys/p.Trp175Ter, confirmed the 
inability of mutant DNAJC12 to properly contribute to the PAH folding process.  
It is remarkable that steady–state TH levels were reduced in the presence of 
DNAJC12 variants in patient–derived fibroblasts, while TPH levels did not seem to 
be affected. Unfortunately, it was not possible to rule out the absence of the 
p.Thr175Ter DNAJC12 mutant protein in the patient-derived fibroblasts due to the 
lack of recognition by the antibody, and if present it may have interacted with TPH, 
assisting with folding. The disappearance of the specific heptapeptide owed to the 
premature stop codon introduced by the p.Trp175Ter variant might have affected 
the correct recognition of PAH and TH by DNAJC12, but not that of the TPH2 
protein.  
It was initially reported that patients with HPA suffered progressive 
dystonia and intellectual disability (Anikster et al., 2017). Later reports broadened 
the clinical spectrum of DNAJC12 deficiency to range from a very mild 
neurological phenotype to early-onset dopa–responsive Parkinsonism (van 
Spronsen et al., 2017), (Straniero et al., 2017). In the light of the present results, the 
more important involvement of the DNAJC12 C–terminal domain in the stability 
of PAH than in other AAAH seems plausible, and might explain the practical 
absence of neurological manifestations in the present patients. These results 
suggest that the phenotypic characteristics expressed depend on the variants 
involved and/or other genetic modifiers. Further, all patients ever reported in the 
literature have presented with reduced CSF HVA and 5-HIAA concentrations, 
 
This article is protected by copyright. All rights reserved. 
 
revealing a central deficit of dopamine and serotonin respectively. Since 
neurotransmitters levels in the CSF were measured only in two patients, it cannot 
be ruled out that they might develop future neurological complications. It might be 
advisable to perform a CSF analysis of neurotransmitter–derived metabolites to 
rule out this possibility, although this test is controversial since most cases in our 
series are currently asymptomatic. 
DNAJC12 overexpression ameliorated the effects of the p.Leu48Ser, 
p.Ile65Thr or p.Arg261Gln variants on PAH stability, but worsened those of the 
p.Glu280Lys, p.Leu348Val and Val388Met variants. Thus, PAH missense 
mutations lead to different degrees of conformational destabilization (Gersting et 
al., 2008). The overexpression of DNAJC12 leads the mutant protein towards the 
stabilization pathway or to its degradation via the ubiquitin–proteasome system 
(Scheller et al., 2019). The different effect of DNAJC12 might depend on the 
different pathogenic mechanism of each variant; thus, those mutants with a 
tendency to aggregate might stabilize after DNAJC12 overexpression while 
mutants with tendency to degrade would not. Further assays are needed to confirm 
this hypothesis. This highlights the major role of DNAJC12 in targeting misfolded 
PAH for degradation (Jung-Kc et al., 2019). These results open up the possible use 
of pharmacological treatments designed to upregulate levels of molecular 
chaperones or co-chaperones.  
DNAJC12 would appear to be a modifier of PAH deficiency, with different 
variants stabilizing/degrading the protein to different degrees. This could explain 
some of the inconsistencies in the genotype–phenotype correlation described in 
patients with PKU, as well as the highly variable response to sapropterin therapy 
reported for people with certain mutant alleles, such as p.Val388Met or Leu348Val 
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(Sarkissian et al., 2012). Further investigations are needed to understand the 
relationship between DNAJC12 and its clients, which would help reveal the role of 
DNAJC12 as a modifier gene in PKU and its involvement in the development of 
neurological disorders. 
In summary, the present work emphasizes the need to perform periodic re-
evaluations of unsolved cases of genetic diseases based on new scientific findings 
in order to confirm the gene affected and prescribe adequate therapy. The 
identification of patients with DNAJC12 deficiency informs on the specific 
biochemical tests (e.g., neurotransmitter analyses) required to assess possible 
clinical complications. Given the high frequency of carriers of the p.Trp175Ter 
pathogenic variant in the Spanish population, there may be many people with 
DNAJC12 deficiency (1/500,000) who were not identified by neonatal mass 
screening, and who might benefit from L-DOPA treatment (Straniero et al., 2017). 
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Titles and legends to figures 
Figure 1. Functional characterization of DNAJC12 patient–derived 
fibroblasts. A) Relative expression of DNAJC12 in control–derived fibroblasts (C) 
and fibroblasts from DNAJC12 patient 14 (p.Trp175Ter/p.Trp175Ter, P14), patient 
16 (p.Trp103Cys/p.Trp175Ter, P16) and patient 20 (p.Trp175Ter/p.Trp175Ter, 
P20) measured by qPCR. Each bar represents the mean ± SD of three independent 
experiments. DNAJC12 mRNA levels were normalized using GAPDH as an 
endogenous control. B) Representative Western blot of DNAJC12 protein from 
control (C) and patient–derived fibroblasts (P14, P20 and P16). β-actin was used as 
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Figure 2. Functional effect of DNAJC12 variants on amino acid hydroxylases. 
A, C, and D) Western blot assays of PAH (A), TH (C) or TPH2 (D) and DNAJC12 
proteins in fibroblasts from a control individual (C lane) and DNAJC12 patients 14 
(p.Trp175Ter/p.Trp175Ter, P14), patient 16 (p.Trp103Cys/p.Trp175Ter, P16) and 
20 (p.Trp175Ter/p.Trp175Ter, P20) after transfection with 5 µg of the 
corresponding plasmid (+ lanes), and the negative control (- lanes). β-actin was 
used as a loading control. B) PAH activity in control and patient–derived 
fibroblasts transfected with 5 µg of plasmid pRC–CMV–PAH, expressed as the 




This article is protected by copyright. All rights reserved. 
 
Figure 3. Role of DNAJC12 in the presence of different PAH mutations. A) 
Representative Western blot of wild–type and different mutant PAH proteins 
overexpressed in COS-7 cells alone (- lanes) or in combination with DNAJC12 (+ 
lanes). 1 µg of each expression plasmid was used for transfection. Neomycin 
phosphotransferase II (NPT-II) was used as a marker of plasmid transfection 
efficiency. β-actin was used as a loading control. B) Quantification of relative PAH 
protein levels after DNAJC12 plasmid co–transfection. The basal PAH level 
without DNAJC12 overexpression was considered as ‘1’. Each bar represents the 
mean ± SD of at least three independent experiments. C) Relative PAH activity 
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DNAJC12 transcript NM_021800.3 
aNormal value >120 µM 
b Normal values: 4,8-23 ng/ml 
c Normal values: 11.9-66 nmol/mmol creatinine 
Table 2. Genotype and phenotype of DNAJC12 deficient patients with 
monoallelic pathogenic variant in PAH 








  Allele 1 Allele 2            






1 month  
10 days 
24 years 6 
months <363 - 





6 days 9 years 6 months 151 31.2 





1 month 29 
days 6 years 163 - 
21 (p.Trp175Ter) c.524G>A ? 
(p.?) 
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DNAJC12 transcript NM_021800.3. PAH transcript NM_000277.3 
aNormal value >120 µM 
b Normal values: 4,8-23 ng/ml 
 
